Skip to main content
SpringerLink
Log in

Update on the Management of Crohn’s Disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Crohn’s disease (CD) is a chronic inflammatory disorder characterized by focal, asymmetric, transmural inflammation of any part of the luminal gastrointestinal tract of uncertain etiology and an unpredictable course. The available treatment options include aminosalicylates, budesonide and systemic corticosteroids, antibiotics, immunomodulators,methotrexate and anti-TNF agents. This review discusses recent developments in the treatment of CD and provides a comprehensive update on management of patients with CD based on the data from randomized controlled trials. Pique

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of outstanding importance

  1. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.

    Article  PubMed  Google Scholar 

  2. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706.

    Article  PubMed  CAS  Google Scholar 

  3. Schwartz DA, Loftus Jr EV, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–80.

    Article  PubMed  Google Scholar 

  4. Clemett D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn’s disease. Drugs. 2000;59:929–56.

    Article  PubMed  CAS  Google Scholar 

  5. Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983;16:738–40.

    PubMed  CAS  Google Scholar 

  6. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study [ECCDS]: results of drug treatment. Gastroenterology. 1984;86:249–66.

    PubMed  CAS  Google Scholar 

  7. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology. 1993;104:1293–301.

    PubMed  CAS  Google Scholar 

  8. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine [5-ASA] preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278–82.

    Article  PubMed  CAS  Google Scholar 

  9. Arber N, Odes HS, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn’s disease in remission. J Clin Gastroenterol. 1995;20:203–6.

    Article  PubMed  CAS  Google Scholar 

  10. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn’s colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut. 2001;49:552–6.

    Article  PubMed  CAS  Google Scholar 

  11. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine [Pentasa] as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives [GETAID]. Gastroenterology. 1993;104:435–9.

    PubMed  CAS  Google Scholar 

  12. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid [Asacol] in the maintenance treatment of Crohn’s disease. The Italian IBD Study Group. Gastroenterology. 1992;103:363–8.

    PubMed  CAS  Google Scholar 

  13. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1997;112:1069–77.

    Article  PubMed  CAS  Google Scholar 

  14. Thomson AB, Wright JP, Vatn M, et al. Mesalazine [Mesasal/Claversal] 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn’s disease. Aliment Pharmacol Ther. 1995;9:673–83.

    Article  PubMed  CAS  Google Scholar 

  15. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn’s disease. Dig Dis Sci. 1992;37:29–32.

    Article  PubMed  CAS  Google Scholar 

  16. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn’s disease: is it useful? Our four years experience. Int J Clin Pharmacol Res. 1994;14:133–8.

    PubMed  CAS  Google Scholar 

  17. de Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn’s disease. Aliment Pharmacol Ther. 1997;11:845–52.

    Article  PubMed  Google Scholar 

  18. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465–73.

    Article  PubMed  CAS  Google Scholar 

  19. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;12:CD008870.

    PubMed  Google Scholar 

  20. •• Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-Aminosalicylates in Crohn’s Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011. This is the most recent and up-to-date meta-analysis of the efficacy of sulfasalazine and newer mesalamine formulations in inducing and maintaining remission in patients with Crohn’s disease. It indicates that mesalamine formulations are not superior to placebo in treatment of Crohn’s disease.

  21. •• Gordon M, Naidoo K, Thomas AG, et al.: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011;1:CD008414. This is the most recent and up-to-date meta-analysis of the efficacy of sulfasalazine and newer mesalamine formulations in maintaining surgically induced remission in patients with Crohn’s disease. This study suggests that mesalamine formulations might be superior to placebo in these patients.

    PubMed  Google Scholar 

  22. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010;4:28–62.

    Article  PubMed  CAS  Google Scholar 

  23. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83. quiz 464, 484. Very comprehensive, up-to-date and evidence based description of the management of Crohn’s disease.

    Article  PubMed  Google Scholar 

  24. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD000296.

  25. Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100:1780–7.

    Article  PubMed  CAS  Google Scholar 

  26. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD002913.

  27. Rutgeerts P. The use of budesonide in the treatment of active Crohn’s disease is good clinical practice. Inflamm Bowel Dis. 2001;7:60–1. discussion 62–3.

    Article  PubMed  CAS  Google Scholar 

  28. Faubion Jr WA, Loftus Jr EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.

    Article  PubMed  CAS  Google Scholar 

  29. Summers RW, Switz DM, Sessions Jr JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–69.

    PubMed  CAS  Google Scholar 

  30. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.

    Article  PubMed  CAS  Google Scholar 

  31. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut. 1997;41:209–14.

    Article  PubMed  CAS  Google Scholar 

  32. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011.

  33. Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001;29–40.

  34. Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn’s disease. J Immunol. 2002;169:5308–14.

    PubMed  Google Scholar 

  35. Friswell M, Campbell B, Rhodes J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver. 2010;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  36. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–31.

    PubMed  CAS  Google Scholar 

  37. Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28:1983–8.

    Article  PubMed  CAS  Google Scholar 

  38. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.

    Article  PubMed  CAS  Google Scholar 

  39. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856–61.

    Article  PubMed  CAS  Google Scholar 

  40. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011.

  41. Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;CD000299.

  42. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD000067.

  43. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–96.

    Article  PubMed  CAS  Google Scholar 

  44. •• Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2011. The most recent meta-analysis of the efficacy of azathioprine or 6-mercaptopurine in patients with Crohn’s disease. This analysis suggests that these agents are not superior to placebo in the treatment of patients with active or inactive Crohn’s disease.

  45. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;CD000067.

  46. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.

    Article  PubMed  CAS  Google Scholar 

  47. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49:656–64.

    Article  PubMed  CAS  Google Scholar 

  48. Peppercom MA. 6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. Am J Gastroenterol. 1996;91:1689–90.

    PubMed  CAS  Google Scholar 

  49. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249–52.

    Article  PubMed  CAS  Google Scholar 

  50. Kotlyar D, Blonski W, Porter D, et al. Hepatosplenic T-cell lymphoma [HSTCL] and inflammatory bowel disease [IBD]: a rare complication after long-term thiopurine exposure: case report and systematic review of the literature. Gastroenterology. 2009;136:A196.

    Article  Google Scholar 

  51. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn’s disease treated with azathioprine. Leuk Lymphoma. 2003;44:531–3.

    Article  PubMed  CAS  Google Scholar 

  52. Rosh JR, Oliva-Hemker M. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. J Pediatr Gastroenterol Nutr. 2007;44:165–7.

    Article  PubMed  Google Scholar 

  53. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–8.

    Article  PubMed  Google Scholar 

  54. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7.

    Article  PubMed  Google Scholar 

  55. •• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.e1. Recent systematic review discussing factors contributing to the development of hepatospelnic T-cell lymphoma in patients treated with azathioprine and/or infliximab.

    Article  PubMed  CAS  Google Scholar 

  56. Kotlyar DS, Gisbert JP, Lewis JD, et al. Overall incidence of hepatosplenic T cell lymphoma in patients with inflammatory bowel disease on thiopurines: a meta-analysis of three population based studies. Abstract accepted for Digestive Disease Week. Chicago, IL. May 7-May 10, 2011. 2011.

  57. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–62.

    PubMed  CAS  Google Scholar 

  58. Reuther LO, Sonne J, Larsen N, et al. Thiopurine methyltransferase genotype distribution in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;17:65–8.

    Article  PubMed  CAS  Google Scholar 

  59. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018–24.

    Article  PubMed  CAS  Google Scholar 

  60. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2005;CD003459.

  61. Patel V, Macdonald JK, McDonald JW, et al. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;CD006884.

  62. Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1158–61.

    PubMed  CAS  Google Scholar 

  63. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin [folinic acid] in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36:795–803.

    Article  PubMed  CAS  Google Scholar 

  64. Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316–28.

    Article  PubMed  CAS  Google Scholar 

  65. Remicade [Infliximab]. Prescribing information. Centocor Ortho Biotech Inc.Malvern, PA. 2009.

  66. Humira [Adalimumab]. Prescribing Information. Abbott Laboratories, North Chicago, IL. 2010.

  67. Cimzia [Certolizumab pegol]. Prescribing information. UCB Inc, Smyrna, GA. 2009.

  68. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–53. A very important meta-analysis demonstrating the efficacy of anti-TNF antibodies in patients with Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  69. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006893.

  70. •• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95. Data from recent SONIC trial suggesting that combination therapy with azathioprine and infliximab is the most efficacious regimen in patients with moderate to severe Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  71. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003;98:2372–82.

    Article  PubMed  CAS  Google Scholar 

  72. Natalizumab [Tysabri]. Prescribing information. Biogen Idec Inc., Cambridge, MA. 2010.

  73. Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest. 2008;118:825–6.

    Article  PubMed  CAS  Google Scholar 

  74. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107198.htm Date accessed: February 1, 2011.

  75. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2007;CD006097.

  76. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.

    Article  PubMed  CAS  Google Scholar 

  77. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med. 2005;353:432–3.

    Article  PubMed  CAS  Google Scholar 

  78. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab–unforeseen consequences. N Engl J Med. 2005;353:414–6.

    Article  PubMed  CAS  Google Scholar 

  79. Lichtenstein GR, Hanauer SB, Kane SV, et al. Crohn’s is not a 6-week disease: lifelong management of mild to moderate Crohn’s disease. Inflamm Bowel Dis. 2004;10 Suppl 2:S2–10.

    PubMed  Google Scholar 

  80. •• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660–7. An important pilot study suggesting that “top down” therapeutic approach [infliximab and azathioprine combined] introduced at the early stage of Crohn’s disease is associated with better outcomes that “step up” [traditional] therapeutic approach.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Gary R. Lichtenstein has worked as a consultant for Abbott Corporation; Alaven; Bristol-Myers Squibb; Centocor Orthobiotech; Elan; Ferring; Meda Pharmaceuticals; Millenium Pharmaceuticals; Pfizer Pharmaceuticals; Proctor and Gamble; Prometheus Laboratories, Inc.; Salix Pharmaceuticals; Santarus; Schering-Plough Corporation; Shire Pharmaceuticals; Warner Chilcotte; UCB; and Wyeth. Anna M. Buchner and Wojciech Blonski reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA

    Anna M. Buchner, Wojciech Blonski & Gary R. Lichtenstein

  2. Department of Gastroenterology, Medical University, Wroclaw, Poland

    Wojciech Blonski

  3. Gastroenterology Division, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA, 19104-4283, USA

    Gary R. Lichtenstein

Authors
  1. Anna M. Buchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wojciech Blonski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary R. Lichtenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary R. Lichtenstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buchner, A.M., Blonski, W. & Lichtenstein, G.R. Update on the Management of Crohn’s Disease. Curr Gastroenterol Rep 13, 465–474 (2011). https://doi.org/10.1007/s11894-011-0220-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-011-0220-x

Key words

Search

Navigation